Longitudinal decline in lung function: a community-based cohort study in Korea

被引:0
作者
Ah Young Leem
Boram Park
Young Sam Kim
Joon Chang
Sungho Won
Ji Ye Jung
机构
[1] Yonsei University College of Medicine,Division of Pulmonology, Department of Internal Medicine, Institute of Chest Disease, Severance Hospital
[2] Seoul National University,Department of Epidemiology and Biostatistics, School of Public Health
来源
Scientific Reports | / 9卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Progressive decline in lung function is the hallmark of chronic obstructive pulmonary disease (COPD). We aimed to assess the rate of decline in forced expiratory volume in 1 second (FEV1) in patients from a community cohort database in Korea. 5,865 subjects aged 40–69 years from the Ansung-Ansan cohort database I–III (2001–2006) were included in this study. We assessed the annual rate of decline in FEV1 over time in relation to smoking status, patient sex, and presence or absence of pre-bronchodilator airflow limitation using a generalized additive mixed model. The mean follow-up duration was 3.8 years. The annual mean decline in FEV1 in the entire cohort was significantly more rapid for men than women (31.3 mL vs 27.0 mL, P = 0.003). Among men without pre-bronchodilator airflow limitation, annual mean declines in FEV1 were 31.5, 35.5, and 40.1 mL for never smokers, former smokers (P = 0.09 vs. never smokers), and current smokers (P < 0.001 vs. never smokers), respectively; and 23.4, 19.7, and 33.9 mL, respectively, for men with pre-bronchodilator airflow limitation. Thus, among Korean males, smoking accelerates lung function decline over time whereas smoking cessation slows the rate of FEV1 decline regardless of pre-bronchodilator airflow limitation. This underscores the importance of smoking cessation in Koreans.
引用
收藏
相关论文
共 98 条
[1]  
Mannino DM(2015)Economic Burden of COPD in the Presence of Comorbidities Chest 148 138-150
[2]  
Mannino DM(2007)Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 765-773
[3]  
Buist AS(1999)Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease N Engl J Med 340 1948-1953
[4]  
Pauwels RA(1977)The natural history of chronic airflow obstruction Br Med J 1 1645-1648
[5]  
Fletcher C(1994)Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study Jama 272 1497-1505
[6]  
Peto R(1999)Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial Lancet 353 1819-1823
[7]  
Anthonisen NR(2000)Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial Bmj 320 1297-1303
[8]  
Vestbo J(2000)Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 343 1902-1909
[9]  
Burge PS(2005)Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial Lancet 365 1552-1560
[10]  
Wise R(2012)Lung function decline in COPD Int J Chron Obstruct Pulmon Dis 7 95-99